The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor
- PMID: 11779507
- DOI: 10.1016/s1097-2765(01)00401-4
The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor
Abstract
We show that Janus kinase 2 (JAK2), and more specifically just its intact N-terminal domain, binds to the erythropoietin receptor (EpoR) in the endoplasmic reticulum and promotes its cell surface expression. This interaction is specific as JAK1 has no effect. Residues 32 to 58 of the JAK2 JH7 domain are required for EpoR surface expression. Alanine scanning mutagenesis of the EpoR membrane proximal region reveals two modes of EpoR-JAK2 interaction. A continuous block of EpoR residues is required for functional, ligand-independent binding to JAK2 and cell surface receptor expression, whereas four specific residues are essential in switching on prebound JAK2 after ligand binding. Thus, in addition to its kinase activity required for cytokine receptor signaling, JAK is also an essential subunit required for surface expression of cytokine receptors.
Similar articles
-
The extended box 2 subdomain of erythropoietin receptor is nonessential for Jak2 activation yet critical for efficient mitogenesis in FDC-ER cells.J Biol Chem. 1994 Jul 15;269(28):18291-4. J Biol Chem. 1994. PMID: 8034573
-
JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.Cell. 1993 Jul 30;74(2):227-36. doi: 10.1016/0092-8674(93)90414-l. Cell. 1993. PMID: 8343951
-
Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo.Blood. 1994 Sep 1;84(5):1501-7. Blood. 1994. PMID: 8068943
-
Quality control of receptor-kinase signaling complexes.Dev Cell. 2002 Jan;2(1):1-2. doi: 10.1016/s1534-5807(01)00114-9. Dev Cell. 2002. PMID: 11782306 Review.
-
On the molecular origins of the chronic myeloproliferative disorders: it all makes sense.Blood. 2005 Jun 1;105(11):4187-90. doi: 10.1182/blood-2005-03-1287. Epub 2005 Apr 7. Blood. 2005. PMID: 15817681 Review. No abstract available.
Cited by
-
Regulation of prolactin receptor levels and activity in breast cancer.J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):81-91. doi: 10.1007/s10911-008-9068-6. Epub 2008 Jan 19. J Mammary Gland Biol Neoplasia. 2008. PMID: 18204982 Free PMC article. Review.
-
TYK2 activity promotes ligand-induced IFNAR1 proteolysis.Biochem J. 2006 Jul 1;397(1):31-8. doi: 10.1042/BJ20060272. Biochem J. 2006. PMID: 16551269 Free PMC article.
-
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.Blood. 2006 Mar 1;107(5):1864-71. doi: 10.1182/blood-2005-06-2600. Epub 2005 Oct 25. Blood. 2006. PMID: 16249382 Free PMC article.
-
JAK inhibitors and COVID-19.J Immunother Cancer. 2022 Apr;10(4):e002838. doi: 10.1136/jitc-2021-002838. J Immunother Cancer. 2022. PMID: 35459733 Free PMC article. Review.
-
Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function.Mol Cell Biol. 2006 Nov;26(22):8527-38. doi: 10.1128/MCB.01035-06. Epub 2006 Sep 18. Mol Cell Biol. 2006. PMID: 16982687 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous